Skip to main content

Table 2 Response assessment criteria

From: Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

  RECIST CHOI mCHOI MASS
Progressive disease (MASS unfavourable response) Increase in sum of longest target lesion diameters >20%.
or
Development of new lesions.
or
Unequivocal non-target lesion progression.
Increase in lesion sizea > 10%.
or
Development of new lesions.
or
New or enlarging intratumoral nodule.
Increase in lesion sizea > 10%.
or
Development of new lesions.
or
New or enlarging intratumoral nodule.
Increase in lesion sizea > 20% without central necrosis.
or
Development of new lesions.
or
New intratumoral enhancing components.
Partial response (MASS favourable response) >30% decrease in sum of longest target lesion diameters. Decrease in target lesion CT enhancement (Hounsfield units) >15% or size >10% Decrease in target lesion CT enhancement (Hounsfield units) >15% and size >10% Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units
Complete response Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm). Disappearance of all target lesions Disappearance of all target lesions Disappearance of all target lesions
Stable disease (MASS indeterminate response) None of the above None of the above None of the above None of the above
  1. aLesion size refers to the sum of the longest diameter of up to 10 target lesions (two per organ)